Advertisement

BMC Pulmonary Medicine

, 19:20 | Cite as

A single-institution study of concordance of pathological diagnoses for interstitial lung diseases between pre-transplantation surgical lung biopsies and lung explants

  • Tanmay S. Panchabhai
  • Andrea Valeria Arrossi
  • Kristin B. Highland
  • Debabrata Bandyopadhyay
  • Daniel A. Culver
  • Marie M. Budev
  • Carol F. FarverEmail author
Open Access
Research article
Part of the following topical collections:
  1. Infectious, Rare and Idiopathic Pulmonary Diseases

Abstract

Background

By comparing diagnoses made by pre-transplant surgical lung biopsy (SLB) and the final pathologic diagnosis of the explanted pathology (EP), we aimed to study the factors that could impact pathologic diagnoses in patients with interstitial lung disease (ILD).

Methods

We retrospectively reviewed the lung transplant database at Cleveland Clinic [01/01/2006–12/31/2013] to include all lung transplant recipients with a prior diagnosis of ILD. Two pulmonary pathologists independently reviewed each SLB and lung explant. The diagnoses were labeled as concordant (same diagnosis on SLB and explant) or discordant (diagnosis on SLB and explant were different) by consensus.

Results

Of 389 patients transplanted for ILD, 217 had an SLB before transplant. Pathological diagnoses were concordant in 190 patients (87.6%) [165 UIP (86.8%), 13 NSIP (6.8%), 8 CHP (4.2%) and 4 other diagnoses (2.1%). In 27 cases (12.4%), the diagnosis on SLB differed from EP. 8/27 were diagnosed with UIP on SLB and of these, 5 were re-classified as NSIP. 14/19 (73.7%) patients with a SLB diagnosis “other than UIP” were re-categorized as UIP based on explant. Discordant cases had a greater time between SLB and EP than concordant cases (1553 days vs 1248 days).

Conclusions

The pathologic diagnosis of ILD by SLB prior to lung transplant is accurate in most patients, but may be misleading in a small subset of patients. The majority of discordant cases that were reclassified as UIP could be due to a sampling error, or perhaps, an increased time from the date of the SLB to transplant. Future studies examining how multidisciplinary consensus diagnosis affects this discordance are necessary.

Keywords

Surgical lung biopsy Explant pathology Interstitial lung disease Lung transplantation Discordant diagnosis 

Abbreviations

ALI

Acute lung injury

CHP

Chronic hypersensitivity pneumonitis

CTD-ILD

Connective tissue disease-associated ILD

DLT

Double lung transplant

ECMO

Extracorporeal membrane oxygenation

EP

Explant pathology

HRCT

High resolution computed tomography

ILD

Interstitial lung disease

ILD-NOS

Interstitial lung disease – not otherwise specified

IPF

Idiopathic pulmonary fibrosis

LAS

Lung Allocation Score

LSLT

Left single lung transplant

NSIP

Nonspecific interstitial pneumonia

RSLT

Right single lung transplant

SLB

Surgical lung biopsy

UIP

Usual interstitial pneumonia

VATS

Video-assisted thoracoscopic surgery

Background

The management of interstitial lung disease (ILD) has undergone a significant paradigm shift over the past decade and with this shift has come an increased demand for accurate diagnosis of ILD. This is especially important for idiopathic pulmonary fibrosis (IPF), which has the worst prognosis and few potential treatment options to slow the progression of disease [1]. Moreover, a definitive diagnosis of IPF also prompts consideration and referral for lung transplantation [1]. The 2015 ATS/ERS/JRS/ALAT Guidelines for diagnosis and management of IPF suggest high-resolution computed tomography (HRCT) for diagnosis [1]. The surgical lung biopsy (SLB), once the gold standard for ILD diagnosis, has given way to “probable” and “definitive” patterns shown to be consistent with a pathologic diagnosis of usual interstitial pneumonia (UIP) on HRCT. A multidisciplinary consensus diagnosis (whether based on SLB pathology or not) is now considered the gold standard for the diagnosis of ILD [2]. The utility of the multidisciplinary consensus diagnosis has been recommended to aid the following scenarios: 1) When clinical context or CT pattern or both are indeterminate, to aid in decision making for additional work-up including bronchoscopy, SLB, etc.; 2) After SLB to evaluate clinical, radiological and pathological findings; 3) Re-review patients in whom the clinical course is discordant with a prior multidisciplinary diagnosis; or 4) When diagnostic tissue is not available and to consider a working diagnosis [2]. SLB was considered to be the gold standard prior to current treatment guidelines [1, 2] and still forms the basis of obtaining diagnostic tissue to aid multidisciplinary consensus [2]. However, conflicting results have been reported regarding the efficacy of single or multiple SLBs on the diagnostic yield for ILD [3, 4].

The pathological diagnoses of UIP and non-specific interstitial pneumonia (NSIP) have received the most attention in prior studies due to their effects on prognosis and survival [5]. Previous research has shown that different patterns may be seen in separate samples obtained from the same patient, resulting in the proposed nomenclature of concordant UIP, discordant UIP, and concordant NSIP [6]. Similarly, early studies comparing diagnoses between SLB and lung explants have demonstrated the presence of NSIP-like pattern in the lungs of patients ultimately diagnosed with UIP [7, 8]. Factors such as the number and areas of the samples, time from surgical lung biopsy to transplantation, and interobserver variability among the reviewing pathologists have been studied in prior reports [6, 9]. Only one study to date has compared the diagnoses on pre-transplantation SLB and explanted lung [7], while 3 others have compared pre-transplant clinical diagnoses to pathological diagnoses made after reviewing the lung explant [10, 11, 12]. All 4 studies have found discordance rates of 10–20% [7, 10, 11, 12]. These studies were carried out before the Lung Allocation Score (LAS) system was introduced in 2005, after which the number of lung transplant recipients for ILD (most commonly IPF) has significantly increased, changing the composition of the patient population reviewed [13]. These studies were done prior to the integration of the current IPF guidelines into clinical practice, which emphasize the role of HRCT in the diagnostic algorithm [1, 7, 10, 11, 12]. Finally, the increased use of pre-transplant mechanical ventilation or extracorporeal membrane oxygenation (ECMO), which may lead to significant acute superimposed pathologic findings in the explanted lung, can make the diagnosis of the underlying ILD on explant even more challenging.

The purpose of this study was to retrospectively evaluate the concordance rate between the pathologic diagnoses made on SLBs and the explant pathology (EP) specimens of lung transplant recipients and to review the possible factors that affected discordant diagnoses.

Methods

Data collection

After approval by the Cleveland Clinic Institutional Review Board (IRB # 14–1489), we retrospectively reviewed the lung transplant database at Cleveland Clinic, Cleveland, OH for all patients who underwent lung and heart–lung transplantations from 01/01/2006–12/31/2013. All patients listed for lung transplantation for a clinical diagnosis of ILD were included. Medical record numbers were retrieved to extract the following data from electronic medical records: patient demographics (e.g., age, sex, and body mass index), transplant date, transplant type, pre-transplant SLB diagnosis, site, number of lobes sampled, time from SLB to lung transplantation and the pathologic diagnostic review (microscopic slides read by Cleveland Clinic pathologists versus outside report review of outside pathologists’ slide review).

Pathological review

Two pathologists (AVA and CFF), both with specialty training in pulmonary pathology, independently reviewed the pathology from all explanted lungs of patients transplanted for ILD and for all pre-transplant SLB where microscopic slides were available, including SLBs performed at outside hospitals. When the original slides of outside SLBs were unavailable for histopathological review, the pathologic diagnosis rendered by the outside pathologist was accepted. Histopathological review between SLB and EP occurred at different time intervals to avoid any confounding bias. ILD was diagnosed according to previously defined diagnostic criteria for usual interstitial pneumonia (UIP), non-specific interstitial pneumonia, cellular or fibrosing type (NSIP-cellular or fibrosing type), desquamative interstitial pneumonia (DIP), chronic hypersensitivity pneumonitis (CHP), acute lung injury or organizing acute lung injury (ALI/org ALI) [14], cryptogenic organizing pneumonia/organizing pneumonia (COP/OP), constrictive bronchiolitis (CB), connective tissue disease-associated interstitial lung disease (CTD-ILD), and interstitial lung disease–not otherwise specified (ILD-NOS) [14].

Discordant UIP (separate UIP and NSIP patterns in different samples of the same patient) has been reported to have outcomes similar to concordant UIP (same UIP pattern in different samples) and significantly worse when compared with concordant NSIP in SLBs [6, 9]. Hence, we conferred a diagnosis of UIP in SLBs if UIP pattern was seen in any of the sampled lobes. In 13 of the 217 cases (5.9%), the pathologists disagreed on the initial review of either the SLB or the explant pathology (EP). In these instances, the case was re-reviewed in order to obtain a mutual consensus. Subjects were categorized as having concordant diagnoses if the diagnosis of SLB and EP were similar. They were categorized as having discordant diagnoses if the final diagnoses of the SLBs and the EP differed. Likewise, the discordant diagnoses category was conferred if there was not a definitive diagnosis (i.e. ILD-NOS or end-stage fibrosis) given to the SLB and a definitive diagnosis was rendered on the EP, or vice versa. The concordant diagnosis category was accepted if the SLB was definitive, but a definitive diagnosis could not be reached on the EP due to the presence of prominent acute lung injury that obscured the underlying fibrotic lung disease.

Results

Demographics

Between 01/01/2006 and 12/31/2013, 774 lung transplantations were performed at Cleveland Clinic. Indications for lung transplantation were: ILD (n = 389, 50.3%), chronic obstructive pulmonary disease (n = 193, 24.9%), cystic fibrosis (n = 84, 10.9%), pulmonary arterial hypertension (n = 41, 5.3%) and others (n = 67, 8.7%). Of the 389 patients transplanted for ILD, 217 (55.8%) underwent SLB before lung transplantation and were the patients included in our study. There were 164 men and 53 women and the mean age at the time of transplantation was 58.90 years. Forty-four patients received right single lung transplant, 65 received left single lung transplant, 107 received bilateral sequential lung transplant, and 1 patient received a heart–lung transplant.

Of the 217 SLBs reviewed, 131 SLBs were from the right side and 86 SLBs were from the left. SLBs were obtained from one lobe in 26 patients (11.9%), from 2 lobes in 127 patients (58.5%) and from 3 lobes in 24 patients (11.0%). Information regarding lobe sampling was not obtained for 40 patients (18.4%). The overall mean time interval between the SLB and transplantation was 1293 days (range 15–8124 days). The distribution of laterality of SLB among the lung transplant recipients was as follows: of the 108 BSLT, 64 had right SLB and 44 had left SLB; of the 44 RSLT, 25 had right SLB and 19 had left SLB and of the 65 LSLT, 42 had right SLB and 23 had left SLB.

Pathologic diagnoses (Tables 1 and 2; Figs. 1 and 2)

The SLB diagnoses included 179 UIP (82.4%), 18 NSIP (8.2%), 10 CHP (4.6%) and 10 miscellaneous (4.6%). Concordance between SLB and EP diagnoses occurred in 190 (87.6%) cases and included 165 UIP (86.8%; 3 cases classified as end-stage interstitial fibrosis with possible UIP pattern), 13 NSIP (6.8%; 3 cases classified as end-stage interstitial fibrosis with possible NSIP pattern), 8 CHP (4.2%) and 4 miscellaneous diagnoses. In 27 cases (12.4%), the diagnoses between SLB and EP were discordant. The final diagnoses based on EP review of the 27 discordant cases were: 14 UIP, 6 NSIP, 2 CHP, 3 ILD-NOS, 1 CTD-ILD, and 1 end-stage fibrosis with pulmonary alveolar proteinosis-like features, suggestive of an environmental etiology. Among the discordant cases, the most common discordances included NSIP on SLB with final diagnosis of UIP on EP (n = 7) and UIP on SLB with final diagnosis of NSIP on EP (n = 5) (Figs. 1 and 2). Together, these two types of discordances comprised 44% of the discordant cases.
Table 1

Discordant diagnoses between surgical lung biopsies and lung explants (n = 27)

No.

Diagnosis on SLB

SLB location

SLB No. of lobes

Diagnosis on Explant

Explanted lung

1

Fibrotic NSIP

Right

2

UIP

Left

2

UIP

Left

N/A

ILD-NOS

Both

3

UIP

Left

N/A

CHP

Left

4

CHP

Right

N/A

UIP

Both

5

NSIP

Left

2

UIP

Both

6

COP

Right

N/A

UIP

Both

7

NSIP

Left

2

UIP

Both

8

DAD

Right

1

NSIP

Both

9

NSIP

Right

2

UIP

Both

10

DIP

Left

N/A

UIP

Both

11

NSIP

Left

2

ILD-NOS

Both

12

UIP

Right

2

Fibrotic NSIP

Both

13

ALI

Right

2

UIP

Both

14

Chronic Bronchiolitis

Right

3

UIP

Both

15

UIP

Right

2

Fibrotic NSIP

Right

16

NSIP

Right

2

UIP

Both

17

UIP

Left

N/A

NSIP

Both

18

BOOP

Right

2

ILD-NOS

Both

19

UIP

Right

N/A

Fibrotic NSIP

Left

20

BOOP

Left

2

UIP

Left

21

Chronic Bronchiolitis

Right

1

CTD-ILD with PAH

Both

22

NSIP

Left

2

UIP

Right

23

NSIP

Right

2

UIP

Both

24

UIP

Right

2

NSIP

Right

25

UIP

Left

2

End-stage IF, likely environmental

Both

26

NSIP

Right

2

CHP

Left

27

ILD-NOS

Left

N/A

UIP

Both

Abbreviations: ALI acute lung injury, BOOP bronchiolitis obliterans organizing pneumonia, CHP chronic hypersensitivity pneumonitis, COP cryptogenic organizing pneumonia, CTD-ILD connective tissue disease-associated interstitial lung disease, DAD diffuse alveolar damage, DIP desquamative interstitial pneumonia, IF idiopathic fibrosis, ILD-NOS interstitial lung disease–not otherwise specified, N/A not available, NSIP non-specific interstitial pneumonia, PAH pulmonary arterial hypertension, SLB surgical lung biopsy, UIP usual interstitial pneumonia

Table 2

Discordant diagnoses between surgical lung biopsies and lung explants (n = 27)

 

Definitive pathological diagnoses from lung explants

Pathological diagnoses made on surgical lung biopsies

UIP

NSIP

CHP

ILD-NOSa

Other diagnoses

UIP

 

5

1

1

1b

NSIP

7

 

1

1

 

CHP

1

    

ILD-NOSa

1

    

ALI

1

    

COP/BOOP

2

  

1

 

DIP

1

    

DAD

 

1

   

Chronic bronchiolitis

1

   

1c

Total n = 27

14

6

2

3

2

aInterstitial fibrosis which is not pathologically classifiable

b Endstage interstitial fibrosis, likely environmental etiology

c Connective tissue disease associated ILD with pulmonary hypertension

Abbreviations: ALI acute lung injury, BOOP bronchiolitis obliterans organizing pneumonia, CHP chronic hypersensitivity pneumonitis, COP cryptogenic organizing pneumonia, DAD diffuse alveolar damage, DIP desquamative interstitial pneumonia, ILD-NOS interstitial lung disease–not otherwise specified, NSIP non-specific interstitial pneumonia, UIP usual interstitial pneumonia

Fig. 1

Pre-transplantation surgical lung biopsy (SLB) in Patient 7: a. SLB revealing chronic inflammation without evidence of fibrosis diffusely involving the lung consistent with non-specific interstitial pneumonia, cellular type. (Hematoxylin and eosin, 12.5x). b. Lymphocytic infiltrate expands the alveolar walls (Hematoxylin and eosin, 100x)

Fig. 2

Explant pneumonectomy in Patient 7: a. Patchy interstitial fibrosis with honeycomb changes (arrow) consistent with usual interstitial pneumonia (UIP). (Hematoxylin and eosin, 12.5x). b. Fibroblastic focus (arrow) confirms UIP diagnosis. (Hematoxylin and eosin, 100x)

We focused on the following variables in the present dataset: number of lobes evaluated, the pathologic review by Cleveland Clinic pulmonary pathologists versus outside pathologists, and the time interval between the SLB and the lung transplantation (Table 3). In the 190 concordant cases, 24 cases had 1 lobe sampled, 111 had 2 lobes sampled, 23 had 3 lobes sampled. In 32 cases, the number of lobes sampled was unknown. The mean time from SLB to explant in these 190 cases was 1248 days (range 15–6855 days). Of the 27 patients for whom diagnoses were discordant between SLB and EP, 2 had 1 lobe sampled, 16 had 2 lobes sampled, 1 had 3 lobes sampled, and the number of samples was unknown in 8 patients. The mean duration of SLB to transplant in these discordant patients was 1553 days (range 29–8124 days). There were 64 SLB diagnoses by Cleveland Clinic pathologists with 5 discordances (7.8%) and 153 diagnoses by outside pathologists with 19 discordances (12.4%).
Table 3

Concordance versus Discordance by Number of Lobes Sampled, Type of Pathology Review and Time from SLB to Transplantation

 

Concordant

Discordant

Total

Number of Lobes Sampled

1 Lobe

24

2

26

2 Lobes

111

16

127

3 Lobes

23

1

24

Unknown

32

8

40

 

190

27

217

Outside Review (OSR) versus Cleveland Clinic (CC) Pathology Review

OSR

134

19

153

CC

59

5

64

Total

190

27

217

Time from SLB to Transplantation (Days)

 

190

27

217

Minimum-Maximum Days to transplant

2–6855

263–8124

 

Average Days

1256.2

1560.3

Discussion

SLB has long been recognized as the gold standard when making a diagnosis of ILD. With advances in management and strict criteria for treatment options, more patients with suspected ILD are undergoing SLB for definitive diagnosis, especially those with atypical clinical and/or radiologic findings. Importantly, a diagnosis of UIP has significant impact on the prognosis and management of patients given the availability of anti-fibrotic therapies such as nintedanib [15] and pirfenidone [16]. Moreover, per guidelines from the International Society of Heart and Lung Transplantation, patients with a diagnosis of UIP should be referred to a lung transplantation center for evaluation of disease progression and candidacy for lung transplantation [17]. However, conflicting data exist regarding the ultimate accuracy of SLB and the factors that may affect it, including the site of the biopsy (i.e., if a more fibrotic area is sampled and if less involved lung is sampled) and number of samples taken [3, 4]. Studies comparing pre-transplant SLB diagnosis with EP pathology provide insight into the possible sources of error for prior clinical-pathological diagnoses.

Samples with an NSIP pattern may be present in patients ultimately diagnosed with UIP [7, 8]. Flaherty et al. defined discordance in the diagnosis of UIP and NSIP from video-assisted thoracoscopic surgery (VATS) samples from the same patient, standardizing terminology with descriptors that include concordant-UIP, discordant-UIP and concordant-NSIP [6]. Likewise, discordance has also been reported in 10–20% of prior studies that compare pre-transplant diagnosis via SLB and diagnosis based on EP [10, 11, 12].

This study represents the largest single-institution study of factors that may affect the discordance rate between SLB and EP pathologic diagnosis. Similar to earlier studies, our results show discordant pathologic diagnosis between SLB and EP in 12.4% of patients. The most common discordant diagnosis included NSIP found in SLB with UIP found in the EP (n = 5) and UIP found in the SLB with NSIP in the EP (n = 7). Our data support our hypothesis that site of SLB, number of lobes sampled and time between SLB and EP could influence concordance. Furthermore, the fewest number of discordant cases were found when 3 lobes were sampled. In those patients who underwent single lung transplant (RSLT = 44, LSLT = 65), 61 had SLBs from the opposite lung (19 left SLB of 44 RSLT and 42 right SLB of 65 LSLT). Of these, only 4 had discordant diagnoses. Our data further expand these findings to include other types of ILDS. Interestingly, 14/19 (73.7%) subjects with a SLB diagnosis “other than UIP” ended up being re-categorized as UIP based on explant. Patients with discordant SLB and EP diagnosis had a longer duration from SLB to EP (1553 vs 1248 days). This suggests a “sampling” error that could be attributed to the size of the biopsies and the place or number of lobes sampled (since discordances were least when 3 lobes were sampled).

Interobserver variability among pathologists may account for discordant diagnoses on SLB with EP. In our study, of the 64 biopsies reviewed by Cleveland Clinic pathologists, there were 5 discordant diagnoses (7.8%). Of the 153 biopsies that were read by outside pathologists, there were 19 discordant diagnoses (12.4%). The difference in these rates of discordance may be explained by 1) both Cleveland Clinic pathologists had previous fellowship training in pulmonary pathology and have worked at an institution with a high volume of lung pathology, and 2) the Cleveland Clinic pulmonary pathologists had clinical and radiologic information during their pathologic evaluation of the SLBs. Nonetheless, the difference in discordance is small. This could perhaps be attributed to the fact that many of the reports of the outside SLBs were reviewed by known pulmonary pathology-trained pathologists with national consultation services. Also, in medical centers where VATS biopsies are performed for ILD, it may indicate a high level of pulmonary pathology skills developed by general surgical pathologists, who have the opportunity to evaluate these biopsies.

Conclusions

New medical therapies are emerging for treatment of patients with ILD. Therefore, it is important that accurate diagnoses are made to ensure selection of patients who will benefit most from these therapies and to identify those who should be immediately referred for lung transplantation. Our study suggests that increasing the number of SLBs taken will increase the odds of a correct/concordant diagnosis. Nevertheless, clinicians should be aware that UIP and NSIP are susceptible to inaccurate pathologic diagnoses. Moreover, with newer techniques such as bronchoscopic cryobiopsies being evaluated for the diagnosis of ILD, the issue of concordance and discordance with explant pathology (arguably the gold standard) becomes even more critical as the size of cryobiopsies is smaller than SLB. In addition, cryobiopsies are not routinely being performed from multiple lobes, based on recommendations for SLB in the ILD diagnostic algorithms. Future studies hence should ideally include comparisons between cryobiopsies, SLB, and multidisciplinary consensus diagnosis as compared to explant diagnosis. Such studies evaluating the effect of a multidisciplinary consensus diagnosis with recommendations of optimal surgical site sampling may reduce discordance between pre-transplantation SLB and explant pathologic diagnosis, improving the management and outcomes in these patients.

Notes

Acknowledgements

Not applicable.

Funding

The authors have no sources of funding to report related to this manuscript.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

TSP, CF, KBH and DAC conceptualized the study and wrote the study protocol. TSP, DB, AVA and CF collected all the study data. AVA and CF analyzed the pathological slides of both SLBs and lung explants. TSP and CF wrote the first draft of the manuscript. All authors (TSP, AVA, KBH, DB, DAC, MMB and CF) were involved in interpretation of the data and they all approved the final draft of the manuscript.

Ethics approval and consent to participate

This study was approved by the Institutional Review Board at Cleveland Clinic in Cleveland, Ohio (IRB # 14–1489).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schünemann HJ, American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–19.  https://doi.org/10.1164/rccm.201506-1063ST.CrossRefPubMedGoogle Scholar
  2. 2.
    Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, Ryu JH, Wells AU. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner society white paper. Lancet Respir Med. 2018;6(2):138–53.  https://doi.org/10.1016/S2213-2600(17)30433-2.CrossRefPubMedGoogle Scholar
  3. 3.
    Fibla JJ, Molins L, Blanco A, Royo I, Martinez Vallina P, Martinez N, et al. Video-assisted thoracoscopic lung biopsy in the diagnosis of interstitial lung disease: a prospective, multi-center study in 224 patients. Arch Bronconeumol. 2012;48(3):81–5.  https://doi.org/10.1016/j.arbres.2011.11.002.CrossRefPubMedGoogle Scholar
  4. 4.
    Han Q, Luo Q, Xie JX, Wu LL, Liao LY, Zhang XX, et al. Diagnostic yield and postoperative mortality associated with surgical lung biopsy for evaluation of interstitial lung diseases: a systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2015;149(5):1394–401 e1.  https://doi.org/10.1016/j.jtcvs.2014.12.057.CrossRefPubMedGoogle Scholar
  5. 5.
    Travis WD, Matsui K, Moss J, Ferrans VJ. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol. 2000;24(1):19–33.CrossRefGoogle Scholar
  6. 6.
    Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med. 2001;164(9):1722–7.  https://doi.org/10.1164/ajrccm.164.9.2103074.CrossRefPubMedGoogle Scholar
  7. 7.
    Katzenstein AL, Zisman DA, Litzky LA, Nguyen BT, Kotloff RM. Usual interstitial pneumonia: histologic study of biopsy and explant specimens. Am J Surg Pathol. 2002;26(12):1567–77.CrossRefGoogle Scholar
  8. 8.
    Rabeyrin M, Thivolet F, Ferretti GR, Chalabreysse L, Jankowski A, Cottin V, et al. Usual interstitial pneumonia end-stage features from explants with radiologic and pathological correlations. Ann Diagn Pathol. 2015;19(4):269–76.  https://doi.org/10.1016/j.anndiagpath.2015.05.003.CrossRefPubMedGoogle Scholar
  9. 9.
    Monaghan H, Wells AU, Colby TV, du Bois RM, Hansell DM, Nicholson AG. Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest. 2004;125(2):522–6.CrossRefGoogle Scholar
  10. 10.
    Calabrese F, Alessandrini L, Loy M, Marulli G, Balestro E, Perissinotto E, et al. Comparison between referral diagnosis of patients requiring transplantation and pathologic diagnosis of native lungs. J Heart Lung Transplant. 2009;28(11):1135–40.  https://doi.org/10.1016/j.healun.2009.05.033.CrossRefPubMedGoogle Scholar
  11. 11.
    Stewart S, Brais R, McNeil K, Wallwork J. Reaudit of the accuracy of referral and histopathological explant diagnoses in lung transplantation. Have we improved? J Heart Lung Transplant. 2002;21(1):84.CrossRefGoogle Scholar
  12. 12.
    Stewart S, McNeil K, Nashef SA, Wells FC, Higenbottam TW, Wallwork J. Audit of referral and explant diagnoses in lung transplantation: a pathologic study of lungs removed for parenchymal disease. J Heart Lung Transplant. 1995;14(6 Pt 1):1173–86.PubMedGoogle Scholar
  13. 13.
    Services UDoHaH. Organ Procurement and Transplantation Network. 2017. https://optn.transplant.hrsa.gov/. Accessed 2/20/2017.
  14. 14.
    Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.  https://doi.org/10.1164/rccm.201308-1483ST.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.  https://doi.org/10.1056/NEJMoa1402584.CrossRefPubMedGoogle Scholar
  16. 16.
    King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.  https://doi.org/10.1056/NEJMoa1402582.CrossRefPubMedGoogle Scholar
  17. 17.
    Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014--an update from the pulmonary transplantation Council of the International Society for heart and lung transplantation. J Heart Lung Transplant. 2015;34:1):1–15.  https://doi.org/10.1016/j.healun.2014.06.014.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Tanmay S. Panchabhai
    • 1
  • Andrea Valeria Arrossi
    • 2
  • Kristin B. Highland
    • 3
  • Debabrata Bandyopadhyay
    • 4
  • Daniel A. Culver
    • 3
  • Marie M. Budev
    • 3
  • Carol F. Farver
    • 2
    Email author
  1. 1.Norton Thoracic Institute, St. Joseph’s Hospital and Medical CenterPhoenixUSA
  2. 2.Department of PathologyPathology and Laboratory Medicine Institute, Cleveland ClinicClevelandUSA
  3. 3.Department of Pulmonary MedicineRespiratory Institute, Cleveland ClinicClevelandUSA
  4. 4.Department of Thoracic MedicineGeisinger Medical CenterDanvilleUSA

Personalised recommendations